Aripiprazole en el tratamiento sintomático del síndrome de Gilíes de la Tourette (enfermedad de los tics) / Aripiprazole for the treatment of Tourette syndrome. Experience in 10 patients
Rev. méd. Chile
; 135(6): 773-776, jun. 2007. graf
Article
em Es
| LILACS
| ID: lil-459582
Biblioteca responsável:
BR1.1
ABSTRACT
Background:
Tourette syndrome is a neuropsychiatric disorder characterized by motor and vocal tics, attentional deficit, poor control of impulses and obsessive compulsive disorder. Pharmacological treatment is often disappointing due to partial response and frequent poor tolerance to neuroleptic drugs which are otherwise the most effective therapy so far.Aim:
To report a lasting improvement obtained with a new drug, aripiprazole that acts modulating both dopaminergic and serotoninergic neurotransmission. Material andmethods:
Ten patients refractory to their usual therapy, aged 10 to 35 years, were switched to aripiprazole in an open trial.Results:
Nine of the 10 patients showed a significant response assessed by the Yale severity tics rating scale and the clinical global impression scale (p <0.01). No relevant adverse effects were observed.Conclusions:
Aripiprazole may be a good pharmacological option for patients with Tourette syndrome.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
LILACS
Assunto principal:
Piperazinas
/
Antipsicóticos
/
Síndrome de Tourette
/
Quinolonas
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
Limite:
Adolescent
/
Adult
/
Child
/
Humans
Idioma:
Es
Revista:
Rev. méd. Chile
Assunto da revista:
MEDICINA
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Chile
País de publicação:
Chile